The Technical Analyst
Pulse Biosciences Inc [PLSE]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Instruments & Supplies
Pulse Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.31% $7.19
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 397.07 mill |
| EPS: | -0.880 |
| P/E: | -8.17 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 55.23 mill |
| Avg Daily Volume: | 0.174 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.17 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.25x |
| Company: PE -8.17 | industry: PE 33.06 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.733 (-89.80%) $-6.46 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.40 - 7.98 ( +/- 11.04%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-12 | Duggan Robert W | Buy | 17 999 | Common Stock |
| 2023-12-11 | Duggan Robert W | Buy | 90 118 | Common Stock |
| 2023-12-08 | Duggan Robert W | Buy | 116 656 | Common Stock |
| 2023-12-07 | Duggan Robert W | Buy | 74 852 | Common Stock |
| 2023-12-06 | Duggan Robert W | Buy | 82 813 | Common Stock |
| INSIDER POWER |
|---|
| 93.07 |
| Last 100 transactions |
| Buy: 20 161 529 | Sell: 636 131 |
Forecast:
16:00 - $7.19
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $7.19
Forecast 2: 16:00 - $7.19
Forecast 3: 16:00 - $7.19
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.19 (-2.31% ) |
| Volume | 0.179 mill |
| Avg. Vol. | 0.174 mill |
| % of Avg. Vol | 102.74 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PLSE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $8.40 | N/A | Active |
|---|
PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Latest Press Releases
2024-03-28 16:12:00 - Press Release
Pulse Biosciences Reports Business Updates And Fourth Quarter & Full Year 2023 Financial Results
Hayward, calif.--(business wire)--pulse biosciences, inc. (nasdaq: plse), a company leveraging its novel and proprietary cellfx® nanosecond pulsed field ablation™ (nspfa™) technology, today announced business updates and financial results for the fourth quarter and full year ended december 31, 2023. recent business highlights cellfx nspfa percutaneous electrode (end-effector of the proprietary designed and engineered cellfx nspfa energy delivery system) received u.s. fda 510(k) clearance for us.
2024-03-28 16:10:00 - Press Release
Pulse Biosciences Announces Plans To Initiate A Rights Offering
Hayward, calif.--(business wire)--pulse biosciences, inc. (nasdaq: plse), a company leveraging its novel and proprietary cellfx® nanosecond pulsed field ablation™ (nspfa™) technology, today announced that its board of directors has unanimously approved plans to initiate a rights offering. the rights offering of up to $60 million worth of units (“units”) will be available to all holders of record of the company's common stock, par value $0.01 (the “common stock”) as of the close of the market on.
2024-03-14 16:05:00 - Press Release
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call For March 28, 2024
Hayward, calif.--(business wire)--pulse biosciences, inc. (nasdaq: plse, “the company”), a company leveraging its novel and proprietary cellfx nanosecond pulsed field ablation™ (nspfa™) technology, today announced it will report financial results for the fourth quarter and full year 2023 after market close on thursday, march 28, 2024. company management will host a corresponding conference call beginning at 1:30pm pt / 4:30pm et. investors interested in listening to the conference call may do s.
2024-03-08 13:17:00 - Press Release
Pulse Biosciences Announces Fda 510(k) Clearance For Its Cellfx® Nspfa™ Percutaneous Electrode System
Hayward, calif.--(business wire)--pulse biosciences, inc. (nasdaq: plse), a company leveraging its novel and proprietary cellfx nanosecond pulsed field ablation™ (nspfa™) technology, today announced receipt of u.s. food and drug administration (fda) 510(k) clearance for its novel cellfx nspfa percutaneous electrode system for use in the ablation of soft tissue in percutaneous and intraoperative surgical procedures. “the fda clearance of our percutaneous electrode system is the initial major mil.
2024-02-14 08:00:00 - Press Release
Pulse Biosciences Announces Positive 60-day Follow-up Evaluations For Initial Patients Treated In The Cellfx® Nspfa™ 360° Cardiac Catheter First-in-human Feasibility Study
Hayward, calif.--(business wire)--pulse biosciences, inc. (nasdaq: plse), a company with a primary focus on leveraging its novel and proprietary cellfx nanosecond pulsed field ablation (nspfa) technology for the treatment of atrial fibrillation, today announced favorable findings from the 60-day post-procedure evaluations for four initial patients treated in the company's cellfx® nspfa™ 360° cardiac catheter first-in-human feasibility study. “the 60-day remap results for the initial patients tr.
Latest News
2024-03-14 16:05:00 - Business Wire
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, March 28, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do s.
2023-11-13 18:16:03 - Seeking Alpha
Pulse Biosciences, Inc. (PLSE) Q3 2023 Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2023 Earnings Conference Call November 13, 2023 12:00 PM ET Company Participants Philip Taylor - IR Kevin Danahy - President and CEO Darrin Uecker - CTO and Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - VP of Finance Bob Duggan - Chairman Conference Call Participants Operator Greetings, and welcome to the Pulse Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
2023-11-10 16:56:00 - Business Wire
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced it will now report financial results for the third quarter of 2023 before market opens on Monday, November 13, 2023. Company management will now host a corresponding conference call beginning at 9:00am PT / 12:00pm ET. Invest.
2023-09-07 16:05:00 - Business Wire
Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to participate at the upcoming Gilmartin Group Emerging Growth Showcase, taking place virtually. Members of management are scheduled to present on Thursday, September 21, 2023 at 10:30am PT. A live and archived webcast of the.
2023-08-10 21:04:11 - Seeking Alpha
Pulse Biosciences Inc. (PLSE) Q2 2023 Earnings Call Transcript
Pulse Biosciences Inc. (NASDAQ:PLSE ) Q2 2023 Results Conference Call August 10, 2023 4:30 PM ET Company Participants Philip Taylor - IR Kevin Danahy - Chief Executive Officer Darrin Uecker - CTO & Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - Director of Finance Bob Duggan - Chariman of the Board of Pulse Biosciences Operator Greetings, and welcome to Pulse Biosciences' Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
2023-05-11 21:59:07 - Seeking Alpha
Pulse Biosciences, Inc. (PLSE) Q1 2023 Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Trip Taylor - Investor Relations Kevin Danahy - President & Chief Executive Officer Darrin Uecker - Chief Technology Officer Mike Koffler - Vice President of Finance Robert Duggan – Executive Chairman Conference Call Participants Robert Lovgren – Medical Hope Productions Operator Good afternoon, ladies and gentlemen and thank you for standing by. Welcome to the Pulse Biosciences First Quarter 2023 Earnings Conference Call.
2023-03-30 20:41:02 - Seeking Alpha
Pulse Biosciences Inc. (PLSE) Q4 2022 Earnings Call Transcript
Pulse Biosciences Inc. (NASDAQ:PLSE ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Trip Taylor – Investor Relations Kevin Danahy – President and Chief Executive Officer Darrin Uecker – Chief Technology Officer Robert Duggan – Executive Chairman Conference Call Participants Robert Lovgren – Medical Hope Productions James Hollingsworth – Private Investor Operator Ladies and gentlemen, greetings, and welcome to the Pulse Biosciences' Fourth Quarter 2022 Earnings Conference Call. At this time all participants lines are in a listen-only mode.
2022-11-10 20:02:07 - Seeking Alpha
Pulse Biosciences, Inc. (PLSE) Q3 2022 Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor – Investor Relations, Gilmartin Group Kevin Danahy – President and Chief Executive Officer Darrin Uecker – Chief Technology Officer Sandy Gardiner – Executive Vice President and Chief Financial Officer Conference Call Participants Operator Greetings and welcome to Pulse Biosciences Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
2022-09-26 14:30:16 - PennyStocks
Hot Penny Stocks To Watch As The Stock Market Crash Continues
2022-08-10 19:40:57 - Seeking Alpha
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2022 Results - Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Darrin Uecker - President and Chief Executive Officer Kevin Danahy - Chief Commercial Officer Sandra Gardiner - Executive Vice President and Chief Financial Officer Conference Call Participants Jeremy Pearlman - Maxim Group LLC Swayampakula Ramakanth - H.C. Wainwright & Co, LLC Operator Greetings, and welcome to Pulse Biosciences Second Quarter 2022 Earnings Conference Call.